Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 16:9:883121.
doi: 10.3389/fmed.2022.883121. eCollection 2022.

Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Affiliations
Review

Scoring Assessments in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Allison S Dobry et al. Front Med (Lausanne). .

Abstract

Epidermal necrolysis, the unifying term for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), is a severe cutaneous drug reaction associated with high morbidity and mortality. Given the rarity of this disease, large-scale prospective research studies are limited. Significant institutional and geographical variations in treatment practices highlight the need for standardization of clinical assessment scores and prioritization of research outcome measures in epidermal necrolysis. At the present, clinical assessment is typically simplified to total body surface area (BSA) involvement, with little focus on morphology. Validated clinical scoring systems are used as mortality prognostication tools, with SCORTEN being the best-validated tool thus far, although the ABCD-10 has also been recently introduced. These tools are imperfect in that they tend to either overestimate or underestimate mortality in certain populations and are not designed to monitor disease progression. Although mortality is often used as a primary endpoint for epidermal necrolysis studies, this outcome fails to capture more nuanced changes in skin disease such as arrest of disease progression while also lacking a validated skin-directed inclusion criterion to stratify patients based on the severity of skin disease at study entry. In addition to mortality, many studies also use BSA stabilization or time to re-epithelialization as endpoints, although these are not clearly defined morphologically, and inter- and intra-rater reliability are unclear. More specific, validated cutaneous assessment scores are necessary in order advance therapeutic options for epidermal necrolysis. In this review, we summarize the strengths and weaknesses of current clinical assessment practices in epidermal necrolysis and highlight the need for standardized research tools to monitor cutaneous involvement throughout the hospitalization.

Keywords: SJS/TEN; dermatology; drug reaction; epidermal necrolysis; scoring assessment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Bioicon representation of the prognostic factors associated with both SCORTEN and ABCD-10 scoring systems. Venous-circulation-body icon by Servier https://smart.servier.com/ is licensed under CC-BY 3.0 Unported https://creativecommons.org/licenses/by/3.0/.

References

    1. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. (2000) 115:149–53. 10.1046/j.1523-1747.2000.00061.x - DOI - PubMed
    1. Kridin K, Brüggen M-C, Chua S-L, Bygum A, Walsh S, Nägeli MC, et al. . Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a pan-European multicenter study. JAMA Dermatol. (2021) 157:1182–90. 10.1001/jamadermatol.2021.3154 - DOI - PMC - PubMed
    1. Duplisea MJ, Roberson ML, Chrisco L, Strassle PD, Williams FN, Ziemer CM. Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. J Am Acad Dermatol. (2021) 85:873–7. 10.1016/j.jaad.2021.04.082 - DOI - PubMed
    1. Phillips EJ, Bouchard CS, Divito SJ. Stevens-johnson syndrome and toxic epidermal necrolysis-coordinating research priorities to move the field forward. JAMA Dermatol. (2022). 10.1001/jamadermatol.2022.0484. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Chang W-C, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, et al. . SJS/TEN 2019: from science to translation. J Dermatol Sci. (2020) 98:2–12. 10.1016/j.jdermsci.2020.02.003 - DOI - PMC - PubMed